Topic research · Biotech
mRNA：分水岭已至，ChatGPT 时刻已排期
Is mRNA at its ChatGPT moment? Our verdict: the watershed event happened on 2026-08-19 — the first-ever positive Phase 3 for an mRNA cancer therapy — but the ChatGPT moment (approval + replication + adoption) is scheduled, not arrived. The next 6–14 months decide it. COVID was the capability shock (the AlphaGo moment); it never converted into durable adoption — revenues fell ~90% and the market priced the pipelines near zero right up to the readout.
History — from lab curiosity to watershed
- 2005 — Karikó & Weissman publish modified-nucleoside breakthrough — immunogenicity problem solved (2023 Nobel Prize)
- 2010–19 — Moderna / BioNTech / CureVac build platforms; delivery (LNP) matures; field stays pre-commercial
- 2020 — COVID: concept-to-authorization in 11 months, ~94% efficacy — the capability shock (mRNA's AlphaGo moment)
- 2021–22 — Peak revenues: Moderna $19.3B, BioNTech €19.0B — then the cliff
- 2023–25 — Post-COVID trough: revenues −85~90%, CureVac fails and is absorbed, US policy turns hostile (HHS cancels ~$500M of mRNA contracts, Aug 2025)
- 2026-08-05 — mFLUSIVA — first mRNA seasonal flu vaccine approved by FDA, under the same restrictive administration
- 2026-08-19 — INTerpath-001: first-ever positive Phase 3 for an mRNA cancer therapy (melanoma, n=1,137, RFS + DMFS met). Moderna +177% in one day — the watershed
Why it's a platform
mRNA is programmable medicine: the same manufacturing line makes any protein by changing the code. Speed (11 months to a novel vaccine), per-patient individualization (≤34 neoantigens selected per melanoma patient), and unit economics that improve with AI — the neoantigen-selection software is emerging as the differentiating asset.
Why it stalled after COVID
Delivery stayed liver-bound (therapeutic protein replacement needs >1000× a vaccine's expression); non-COVID respiratory franchises failed commercially; and US policy turned structurally hostile — ~$500M of federal mRNA contracts cancelled in Aug 2025. The first inhaled human delivery proof (May 2026) and the 8/19 Phase 3 are what changed the slope.
Moderna (MRNA)
Pure-play platform. Cancer (intismeran, 50/50 with Merck), rare disease (mRNA-3927 registrational), respiratory. Repriced $25B → ~$69B on 8/19.
BioNTech (BNTX)
€16.6B cash pile; oncology pivot — but its biggest bet (BNT327, BMS $11.1B deal) is an antibody, not mRNA. iNeST mRNA readouts 2027. Absorbed CureVac (2026).
Arcturus (ARCT)
Self-amplifying mRNA: KOSTAIVE approved EU/Japan/UK — world's only approved saRNA, now partner-less (CSL exited). Inhaled CF program at Phase 3 decision, Q4 2026.
Merck (MRK)
50/50 partner on intismeran across 9 Ph2/3 trials — the big-pharma validation and distribution muscle behind the cancer program.
Capstan → AbbVie
In-vivo mRNA CAR-T (tLNP): acquired for $2.1B (2025) — the delivery frontier beyond vaccines.
China cluster
Abogen et al.; leads circular-RNA clinical translation (first patient dosed, first FDA circRNA IND) while US holds the megadeals.
Decision events — what settles the ChatGPT question
- Oct 2026 (ESMO, expected) — INTerpath-001 full dataset — the effect size. Hazard ratios were NOT disclosed at interim; this is the highest-information event.
- Late 2026–2027 — Intismeran BLA filing & FDA action — does a hostile HHS process the first mRNA cancer application on the science?
- By end-2026 — mRNA-3927 propionic acidemia registrational data — mRNA as chronic systemic therapeutic.
- Q4 2026 — Arcturus ARCT-032 Phase 3 go/no-go — first non-liver mRNA therapeutic into Phase 3.
- 2026–2027 — BioNTech/Roche cevumeran readouts — replication by a second sponsor, or INTerpath reads combo-specific.
- 2026-27 flu season — mFLUSIVA commercial uptake — first test of a new mRNA vaccine under the restrictive US policy regime.